ArticleJournal of translational medicine2026
Long noncoding RNA PCAT7 confers radioresistance of esophageal squamous cell carcinoma by promoting GCLM-mediated anti-ferroptosis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundRadiotherapy is one of the standard treatments for advanced esophageal squamous cell carcinoma (ESCC), but the prognosis remains poor due to radioresistance of tumor cells. Emerging evidence implicates ferroptosis and long non-coding RNAs (lncRNAs) in the mechanisms of radioresistance. Through bioinformatics analysis, we identified lncRNA PCAT7 as a ferroptosis-associated lncRNA biomarker in ESCC. However, the role and mechanism of PCAT7 in radioresistance and ferroptosis of ESCC remain unclear.
methodsBioinformatics analysis was used to identify PCAT7 as a differentially expressed ferroptosis-related lncRNA in ESCC. Functional validation demonstrated its oncogenic properties through proliferation (CCK-8/colony formation assays), migration (transwell assay), and radioresistance (flow cytometry/xenografts assays), while ROS/MDA quantification and Western blot confirmed its anti-ferroptosis activity. RNA sequencing was conducted to confirm the downstream target genes and signaling pathways mediated by PCAT7. RNA immunoprecipitation assay, actinomycin D RNA stability experiment and rescue experiment were performed to identify the mechanism by which PCAT7 conferred ESCC radioresistance.
resultsPCAT7 up-regulation was consistently detected in both ESCC patient specimens and ESCC cell lines. Genetic silencing of PCAT7 attenuated the aggressive phenotype and radiation resistance of ESCC cell lines through ferroptosis activation, as demonstrated in cellular and animal models. Furthermore, PCAT7 could activate the PI3K/AKT signaling pathway by promoting the glutamate-cysteine ligase modifier subunit (GCLM), an anti-ferroptosis protein, thereby facilitating radioresistance of ESCC cells. Moreover, FTO-mediated demethylated N6-methyladenosine participated in the upregulation of PCAT7.
conclusionsPCAT7 inhibited ferroptosis and enhanced radioresistance via GCLM /PI3K/AKT signaling axis in ESCC, a process modulated by FTO-mediated N6-methyadenosine (m6A) demethylation. Our study reveals PCAT7 as a pro-radioresistance lncRNA and potential therapeutic target for enhancing efficiency of radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.